• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors

    5/16/25 4:10:00 PM ET
    $HSIC
    $KKR
    Medical Specialities
    Health Care
    Investment Managers
    Finance
    Get the next $HSIC alert in real time by email

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein.

    In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Health Care industry team in the Americas, who became a member of Henry Schein's Board of Directors on May 2, 2025.

    Max Lin leads the Health Care industry team within KKR, and since joining in 2005, he has overseen a number of investments in the areas of dental services and other health care providers, medical products and equipment, and health care software and information technology. Dan Daniel has over three decades of global leadership experience in industrial and health care sectors, including 14 years as Executive Vice President at Danaher, where he oversaw multiple segments and played a key role in advancing the company's culture and business system. In connection with each of their appointments, Mr. Lin was appointed to the Nominating and Governance Committee as Vice Chair; Mr. Daniel was appointed to the Compensation Committee; and each of Mr. Lin and Mr. Daniel was appointed to the Strategic Advisory Committee.

    "We are pleased to welcome Max and Dan to the Board as we embark on this exciting next chapter for Henry Schein," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. "Their deep experience in health care, operations, and strategic growth will be invaluable as we continue executing on our BOLD+1 strategy and creating long-term value for our stakeholders."

    About Henry Schein, Inc.

    Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

    Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.

    A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company's sales reached $12.7 billion in 2024, and have grown at a compound annual rate of approximately 11.2 percent since Henry Schein became a public company in 1995.

    For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, LinkedIn.com/Company/HenrySchein, and @HenrySchein on X.

    About KKR

    KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE:KKR), please visit KKR's website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at www.globalatlantic.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250516439220/en/

    Investors

    Ronald N. South

    Senior Vice President and Chief Financial Officer

    [email protected]

    (631) 843-5500



    Graham Stanley

    Vice President, Investor Relations and Strategic Financial Project Officer

    [email protected]

    (631) 843-5500



    Media

    Henry Schein

    Tim Vassilakos

    Executive Director, Global Corporate Communications

    [email protected]

    (516) 510-0926



    KKR

    Liidia Liuksila

    [email protected]

    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC
    $KKR

    CompanyDatePrice TargetRatingAnalyst
    KKR & Co. Inc.
    $KKR
    2/24/2026$137.00Outperform
    RBC Capital Mkts
    Henry Schein Inc.
    $HSIC
    2/23/2026$100.00Neutral → Outperform
    Robert W. Baird
    KKR & Co. Inc.
    $KKR
    1/28/2026$144.00Hold → Buy
    HSBC Securities
    KKR & Co. Inc.
    $KKR
    1/14/2026$131.00Buy → Hold
    TD Cowen
    KKR & Co. Inc.
    $KKR
    12/11/2025$176.00Buy
    UBS
    Henry Schein Inc.
    $HSIC
    12/9/2025$86.00Overweight
    Barclays
    Henry Schein Inc.
    $HSIC
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    Henry Schein Inc.
    $HSIC
    7/25/2025$75.00Buy → Hold
    Stifel
    More analyst ratings

    $HSIC
    $KKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barakett Timothy R bought $4,723,500 worth of shares (50,000 units at $94.47) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/5/26 7:30:13 PM ET
    $KKR
    Investment Managers
    Finance

    Director Dillon Mary N bought $2,021,586 worth of shares (22,225 units at $90.96) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:01 PM ET
    $KKR
    Investment Managers
    Finance

    Co-Chief Executive Officer Bae Joseph Y bought $4,428,000 worth of shares (50,000 units at $88.56) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:04 PM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    SEC Filings

    View All

    SEC Form DEFA14A filed by KKR & Co. Inc.

    DEFA14A - KKR & Co. Inc. (0001404912) (Filer)

    3/23/26 4:16:52 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form 144 filed by Henry Schein Inc.

    144 - HENRY SCHEIN INC (0001000228) (Subject)

    3/19/26 12:30:49 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by KKR & Co. Inc.

    DEFA14A - KKR & Co. Inc. (0001404912) (Filer)

    3/13/26 5:17:56 PM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CoolIT Employees Share in $4.75 Billion Transaction as KKR Agrees to Sell to Ecolab

    KKR and its investors achieve 15x return 100% of CoolIT employees receive significant payouts KKR, a leading global investment firm, today announced that it has entered into a definitive agreement to sell CoolIT Systems ("CoolIT" or "the Company"), a global leader in liquid data center cooling, to Ecolab in a transaction valued at $4.75 billion. The sale will represent one of KKR's largest recent realizations, generating approximately 15x the original equity invested, inclusive of distributions. At the close of the transaction, all CoolIT employees will receive a substantial cash payout on their ownership in the Company. Mubadala Investment Company ("Mubadala") also served as a co-inves

    3/25/26 4:30:00 PM ET
    $KKR
    Investment Managers
    Finance

    KKR Announces Intra-Quarter Monetization Activity Update for the First Quarter

    KKR today announced income from monetization activity in excess of $700 million with respect to the period from January 1, 2026 through March 23, 2026 based on information available as of today. The quarter-to-date monetization activity is made up of approximately 90% realized performance income and approximately 10% realized investment income. The quarter-to-date monetization activity is driven by a combination of public secondary sales and strategic transactions, as well as dividends and interest income. The estimate disclosed above is not intended to predict or represent total realized performance income, total realized investment income or total revenues for the full quarter ending

    3/23/26 4:15:00 PM ET
    $KKR
    Investment Managers
    Finance

    KKR Forms $310 Million Strategic Partnership with PMI Electro to Scale E-Bus Platform Allfleet

    Transaction marks milestone first KKR Global Climate Transition investment in India KKR, a leading global investment firm, Allfleet India Private Limited ("Allfleet"), and PMI Electro Mobility Private Limited ("PMI Electro"), a manufacturer of electric commercial vehicles in India, today announced the signing of definitive agreements under which KKR-managed funds will commit up to $310 million to form a strategic partnership with Allfleet and PMI Electro to help scale Allfleet's electric bus ("e-bus") platform and further advance PMI Electro's manufacturing capabilities. As part of the investment, KKR will acquire a majority stake in Allfleet and minority stake in PMI Electro. This marks

    3/17/26 10:00:00 PM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Popeck Thomas C

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    3/20/26 4:07:39 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SVP & Chief Financial Officer South Ronald N. covered exercise/tax liability with 5,216 shares, decreasing direct ownership by 6% to 88,930 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    3/17/26 4:17:50 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SVP, Chief Human Res. Officer Sheehy Christine Zayac covered exercise/tax liability with 463 shares, decreasing direct ownership by 2% to 18,454 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    3/17/26 4:15:54 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $KKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on KKR with a new price target

    RBC Capital Mkts initiated coverage of KKR with a rating of Outperform and set a new price target of $137.00

    2/24/26 7:55:00 AM ET
    $KKR
    Investment Managers
    Finance

    Henry Schein upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Henry Schein from Neutral to Outperform and set a new price target of $100.00

    2/23/26 8:29:17 AM ET
    $HSIC
    Medical Specialities
    Health Care

    KKR upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded KKR from Hold to Buy and set a new price target of $144.00

    1/28/26 7:11:28 AM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Financials

    Live finance-specific insights

    View All

    KKR Announces Intra-Quarter Monetization Activity Update for the First Quarter

    KKR today announced income from monetization activity in excess of $700 million with respect to the period from January 1, 2026 through March 23, 2026 based on information available as of today. The quarter-to-date monetization activity is made up of approximately 90% realized performance income and approximately 10% realized investment income. The quarter-to-date monetization activity is driven by a combination of public secondary sales and strategic transactions, as well as dividends and interest income. The estimate disclosed above is not intended to predict or represent total realized performance income, total realized investment income or total revenues for the full quarter ending

    3/23/26 4:15:00 PM ET
    $KKR
    Investment Managers
    Finance

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    FS KKR Capital Corp. Announces Fourth Quarter and Full Year 2025 Results; Declares First Quarter 2026 Distribution of $0.48 per Share

    PHILADELPHIA and NEW YORK, Feb. 25, 2026 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK), or the Company, today announced its financial and operating results for the quarter and year ended December 31, 2025, and that its board of directors has declared a first quarter 2026 distribution of $0.48 per share. Financial and Operating Highlights for the Quarter Ended December 31, 2025(1)Net investment income of $0.48 per share, compared to $0.57 per share for the quarter ended September 30, 2025Adjusted net investment income(2) of $0.52 per share, compared to $0.57 per share for the q

    2/25/26 4:15:00 PM ET
    $FSK
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Leadership Updates

    Live Leadership Updates

    View All

    KKR-led Consortium Drives Further Investment in Sylvan

    Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the "Company"), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/ Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential

    1/20/26 8:02:00 PM ET
    $KKR
    Investment Managers
    Finance

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    $HSIC
    $KKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/12/24 3:50:17 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care